Cadrenal Therapeutics Announces Executive Changes and Board Updates
Ticker: CVKD · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1937993
Sentiment: neutral
Topics: executive-change, board-composition, filing
TL;DR
Cadrenal Therapeutics is shuffling execs and board members, filing 8-K with details.
AI Summary
Cadrenal Therapeutics, Inc. announced on November 24, 2025, the departure of Dr. Michael L. R. Freeman from his role as Chief Medical Officer. The company also reported on the election of new directors and the appointment of certain officers, alongside compensatory arrangements for these individuals. The filing also includes financial statements and exhibits.
Why It Matters
Changes in key executive positions and board composition can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Executive departures and board changes can introduce uncertainty regarding leadership stability and strategic direction.
Key Numbers
- 001-41596 — SEC File Number (Identifies the company's filing with the SEC.)
- 88-0860746 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Cadrenal Therapeutics, Inc. (company) — Registrant
- Dr. Michael L. R. Freeman (person) — Departing Chief Medical Officer
- November 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41596 (company_id) — SEC File Number
FAQ
Who has departed from Cadrenal Therapeutics, Inc.?
Dr. Michael L. R. Freeman has departed from his role as Chief Medical Officer.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 24, 2025.
What are the main items covered in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements, other events, and financial statements and exhibits.
In which state is Cadrenal Therapeutics, Inc. incorporated?
Cadrenal Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Cadrenal Therapeutics, Inc.?
The principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida 32082.
Filing Stats: 987 words · 4 min read · ~3 pages · Grade level 10.5 · Accepted 2025-12-01 09:05:24
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar
- $35,000 — December 31, 2025, is an annual fee of $35,000 for serving on the Board as well as equ
Filing Documents
- ea0267189-8k_cadrenal.htm (8-K) — 31KB
- ea026718901ex99-1_cadrenal.htm (EX-99.1) — 9KB
- 0001213900-25-116307.txt ( ) — 209KB
- cvkd-20251124.xsd (EX-101.SCH) — 3KB
- cvkd-20251124_lab.xml (EX-101.LAB) — 33KB
- cvkd-20251124_pre.xml (EX-101.PRE) — 22KB
- ea0267189-8k_cadrenal_htm.xml (XML) — 4KB
02. Departure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 24, 2025, the Board of Directors (the "Board") of Cadrenal Therapeutics, Inc. (the "Company") appointed Lee Scott Golden, M.D. ("Dr. Golden"), to serve as a Class II director of the Company to hold office until the 2027 annual meeting of stockholders, at which time his term of office shall expire and a Class II director shall be elected for a full term of three years, or until his re-election or earlier resignation or removal. Dr. Golden was also appointed to serve on the Board's Science and Technology Committee. Dr. Golden currently serves as the Executive Vice President and Chief Medical Officer of PTC Therapeutics, Inc. ("PTC"), positions he has held since April 2023. Dr. Golden previously served as Chief Medical Officer of PTC from January 2022 to April 2023 and as its Senior Vice President, Head of Global Clinical Development from May 2020 to January 2022. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc.. This former privately held development-stage cardiovascular pharmaceutical company focused on the development of drugs for unmet needs in thrombosis and cardiac rhythm control, from October 2018 to May 2020, and as Chief Medical Officer of Gemphire Therapeutics, Inc., a former publicly-traded clinical-stage biopharmaceutical company that was developing and commercializing therapies for cardiometabolic disorders, where he oversaw clinical development and regulatory activities, from October 2016 to September 2018. Dr. Golden has also served on the board of directors of Coagulation Sciences LLC, a privately held medical device company specializing in blood transfusion devices, since December 2012. Dr. Golden has more than 25 years of industry experience, with increasing responsibilities, managing global, cross-functional teams responsible for creatin
01. Other Events
Item 8.01. Other Events. On December 1, 2025, the Company issued a press release announcing the appointment of Dr. Golden to the Board. Such press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 Form of Indemnification Agreement (Incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023) 99.1 Press Release of Cadrenal Therapeutics, Inc. dated December 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 1, 2025 CADRENAL THERAPEUTICS, INC. By: /s/ Quang X. Pham Name: Quang X. Pham Title: Chairman and Chief Executive Officer 2